Cantor Fitzgerald Comments on Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Kura Oncology in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($2.94) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Scotiabank cut their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Stock Performance

KURA opened at $7.70 on Thursday. The firm’s 50-day moving average price is $8.04 and its 200-day moving average price is $13.51. The company has a market cap of $598.78 million, a P/E ratio of -3.26 and a beta of 0.85. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million.

Insider Buying and Selling

In other news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is owned by company insiders.

Institutional Trading of Kura Oncology

Several institutional investors have recently made changes to their positions in the company. Virtus ETF Advisers LLC boosted its position in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after buying an additional 3,061 shares during the period. Harbor Advisors LLC acquired a new stake in shares of Kura Oncology in the fourth quarter valued at $87,000. E Fund Management Co. Ltd. acquired a new position in shares of Kura Oncology during the fourth quarter worth about $90,000. Corton Capital Inc. acquired a new position in shares of Kura Oncology in the 4th quarter valued at $99,000. Finally, Optimize Financial Inc acquired a new stake in Kura Oncology during the 4th quarter worth $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.